|
Market Closed -
Other stock markets
|
After hours 05:30:00 am | |||
| 11.44 USD | +5.63% |
|
12.24 | +7.04% |
| 09/07 | FMC Files First Global Regulatory Submission for Rimisoxafen to US EPA | MT |
| 09/07 | FMC Corporation Submits Regulatory Dossier for Rimisoxafen to United States Environmental Protection Agency | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 504.52Cr | 580.23Cr | 448.68Cr | 424.61Cr | 346.74Cr | |||||
Total Revenues | 504.52Cr | 580.23Cr | 448.68Cr | 424.61Cr | 346.74Cr | |||||
Cost of Goods Sold, Total | 287.35Cr | 347.55Cr | 265.58Cr | 259.72Cr | 229.51Cr | |||||
Gross Profit | 217.17Cr | 232.68Cr | 183.1Cr | 164.89Cr | 117.23Cr | |||||
Selling General & Admin Expenses, Total | 71Cr | 78Cr | 73Cr | 64Cr | 66Cr | |||||
R&D Expenses | 30Cr | 31Cr | 33Cr | 28Cr | 27Cr | |||||
Other Operating Expenses | - | - | 8.87Cr | 9.12Cr | 71L | |||||
Other Operating Expenses, Total | 101.84Cr | 108.94Cr | 115.18Cr | 101.38Cr | 93Cr | |||||
Operating Income | 115.33Cr | 123.74Cr | 68Cr | 64Cr | 24Cr | |||||
Interest Expense, Total | -13Cr | -15Cr | -24Cr | -24Cr | -24Cr | |||||
Interest And Investment Income | - | - | - | - | - | |||||
Net Interest Expenses | -13Cr | -15Cr | -24Cr | -24Cr | -24Cr | |||||
Income (Loss) On Equity Invest. | - | - | - | - | - | |||||
Currency Exchange Gains (Loss) | - | - | -7.52Cr | - | - | |||||
EBT, Excl. Unusual Items | 102.22Cr | 108.56Cr | 37Cr | 40Cr | 6L | |||||
Restructuring Charges | -2.44Cr | 2.61Cr | -4.84Cr | -30Cr | -177.57Cr | |||||
Merger & Related Restructuring Charges | -1.71Cr | - | - | - | - | |||||
Gain (Loss) On Sale Of Investments | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Assets | - | - | - | 17Cr | - | |||||
Asset Writedown | - | - | - | - | -19Cr | |||||
Legal Settlements | - | - | - | - | - | |||||
Other Unusual Items | -8.69Cr | -13Cr | -1.82Cr | -1.82Cr | 8.33Cr | |||||
EBT, Incl. Unusual Items | 89Cr | 98Cr | 30Cr | 25Cr | -188.66Cr | |||||
Income Tax Expense | 9.16Cr | 15Cr | -111.93Cr | -15Cr | 31Cr | |||||
Earnings From Continuing Operations | 80Cr | 84Cr | 141.95Cr | 40Cr | -220.08Cr | |||||
Earnings Of Discontinued Operations | -6.82Cr | -9.72Cr | -9.85Cr | -6.18Cr | -3.66Cr | |||||
Net Income to Company | 73Cr | 74Cr | 132.1Cr | 34Cr | -223.74Cr | |||||
Minority Interest | 25L | -50L | 5L | -5L | -15L | |||||
Net Income - (IS) | 74Cr | 74Cr | 132.15Cr | 34Cr | -223.89Cr | |||||
Preferred Dividend and Other Adjustments | 18L | 17L | 27L | 12L | 11L | |||||
Net Income to Common Incl Extra Items | 73Cr | 73Cr | 131.88Cr | 34Cr | -224Cr | |||||
Net Income to Common Excl. Extra Items | 80Cr | 83Cr | 141.73Cr | 40Cr | -220.34Cr | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 5.72 | 5.83 | 10.55 | 2.72 | -17.9 | |||||
Basic EPS - Continuing Operations | 6.25 | 6.6 | 11.33 | 3.21 | -17.6 | |||||
Basic Weighted Average Shares Outstanding | 13Cr | 13Cr | 13Cr | 13Cr | 13Cr | |||||
Net EPS - Diluted | 5.7 | 5.8 | 10.51 | 2.71 | -17.9 | |||||
Diluted EPS - Continuing Operations | 6.23 | 6.57 | 11.29 | 3.2 | -17.6 | |||||
Diluted Weighted Average Shares Outstanding | 13Cr | 13Cr | 13Cr | 13Cr | 13Cr | |||||
Normalized Basic EPS | 5 | 5.35 | 1.84 | 1.99 | -0.01 | |||||
Normalized Diluted EPS | 4.97 | 5.32 | 1.83 | 1.99 | -0.01 | |||||
Dividend Per Share | 1.97 | 2.17 | 2.32 | 2.32 | 1.82 | |||||
Payout Ratio | 33.56 | 36.32 | 21.98 | 85.19 | -13.01 | |||||
Supplemental Items | ||||||||||
EBITDA | 132.42Cr | 140.68Cr | 86Cr | 81Cr | 41Cr | |||||
EBITA | 121.6Cr | 129.8Cr | 74Cr | 70Cr | 31Cr | |||||
EBIT | 115.33Cr | 123.74Cr | 68Cr | 64Cr | 24Cr | |||||
EBITDAR | 136.28Cr | 144.6Cr | 91Cr | 86Cr | 46Cr | |||||
Effective Tax Rate - (Ratio) | 10.25 | 14.76 | -372.85 | -59.76 | -16.65 | |||||
Current Domestic Taxes | -1.47Cr | 4.58Cr | 5.96Cr | 2.92Cr | 40L | |||||
Current Foreign Taxes | 9.66Cr | 15Cr | 11Cr | 16Cr | 54L | |||||
Total Current Taxes | 8.19Cr | 20Cr | 17Cr | 19Cr | 94L | |||||
Deferred Domestic Taxes | 1.68Cr | -2.53Cr | -8.08Cr | -6.84Cr | 95L | |||||
Deferred Foreign Taxes | -71L | -2.74Cr | -121.2Cr | -27Cr | 30Cr | |||||
Total Deferred Taxes | 97L | -5.27Cr | -129.28Cr | -34Cr | 30Cr | |||||
Normalized Net Income | 64Cr | 67Cr | 23Cr | 25Cr | -11.25L | |||||
Interest Capitalized | 34L | 56L | 93L | 96L | 1.2Cr | |||||
Non-Cash Pension Expense | 2.07Cr | 93L | 1.87Cr | 1.89Cr | 1.37Cr | |||||
Supplemental Operating Expense Items | ||||||||||
Research And Development Expense From Footnotes | 30Cr | 31Cr | 33Cr | 28Cr | 27Cr | |||||
Net Rental Expense, Total | 3.86Cr | 3.92Cr | 4.65Cr | 4.87Cr | 4.45Cr | |||||
Imputed Operating Lease Interest Expense | 1.23Cr | 1.46Cr | 2.44Cr | 2.52Cr | 2.33Cr | |||||
Imputed Operating Lease Depreciation | 2.63Cr | 2.46Cr | 2.21Cr | 2.35Cr | 2.12Cr | |||||
Stock-Based Comp., SG&A Exp. (Total) | 1.78Cr | 2.42Cr | 2.59Cr | 2.38Cr | 2.4Cr | |||||
Total Stock-Based Compensation | 1.78Cr | 2.42Cr | 2.59Cr | 2.38Cr | 2.4Cr |
- Stock Market
- Stocks
- FMC Stock
- Financials FMC Corporation
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















